Skip to main content
Atrás
BMRN logo

BioMarin Pharmaceutical Inc.

Calidad de datos: 100%
BMRN
NASDAQ Healthcare Biotechnology
$54.09
▼ $0.69 (-1.26%)
Cap. Mercado: 10.40B
Rango del Día
$53.36 $54.37
Rango de 52 Semanas
$50.76 $73.18
Volumen
1,648,594
Promedio 50D / 200D
$58.63 / $56.59
Cierre Anterior
$54.78

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (627 pares)

Métrica Acción Mediana del Sector
P/E 29.8 0.3
P/B 1.7 2.9
ROE % 5.9 3.7
Net Margin % 10.8 3.8
Rev Growth 5Y % 14.9 10.0
D/E 0.1 0.2

Precio Objetivo de Analistas

Hold
$86.60 +60.1%
Low: $60.00 High: $105.00
P/E Futuro
12.7
EPS Futuro
$4.32
Crecimiento EPS (est.)
+0.0%
Ingresos Est.
3.6 B

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $8.40
$7.98 – $8.82
5.1 B 6
FY2029 $7.57
$7.19 – $7.96
4.8 B 6
FY2028 $6.76
$4.90 – $9.01
4.4 B 8

Puntos Clave

Revenue grew 14.93% annually over 5 years — strong growth
Earnings declined -18.26% over the past year
Debt/Equity of 0.11 — conservative balance sheet
Generating 724.96M in free cash flow
Cash machine — converts 207.78% of earnings into free cash flow
Capital efficient — spends only 3.20% of revenue on capex

Crecimiento

Revenue Growth (5Y)
14.93%
Revenue (1Y)12.87%
Earnings (1Y)-18.26%
FCF Growth (3Y)240.39%

Calidad

Return on Equity
5.94%
ROIC5.95%
Net Margin10.83%
Op. Margin16.56%

Seguridad

Debt / Equity
0.11
Current Ratio5.21
Interest Coverage48.95

Valoración

P/E Ratio
29.82
P/B Ratio1.71
EV/EBITDA18.25
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 12.87% Revenue Growth (3Y) 15.39%
Earnings Growth (1Y) -18.26% Earnings Growth (3Y) 44.26%
Revenue Growth (5Y) 14.93% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3.22B Net Income (TTM) 348.90M
ROE 5.94% ROA 4.59%
Gross Margin 77.13% Operating Margin 16.56%
Net Margin 10.83% Free Cash Flow (TTM) 724.96M
ROIC 5.95% FCF Growth (3Y) 240.39%
Safety
Debt / Equity 0.11 Current Ratio 5.21
Interest Coverage 48.95 Dividend Yield 0.00%
Valuation
P/E Ratio 29.82 P/B Ratio 1.71
P/S Ratio 3.23 PEG Ratio -1.71
EV/EBITDA 18.25 Dividend Yield 0.00%
Market Cap 10.40B Enterprise Value 9.73B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3.22B 2.85B 2.42B 2.10B 1.85B
Net Income 348.90M 426.86M 167.65M 141.56M -64.08M
EPS (Diluted) 1.80 2.21 0.88 0.75 -0.35
Gross Profit 2.48B 2.27B 1.89B 1.59B 1.38B
Operating Income 533.48M 484.21M 185.77M 160.97M -82.34M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7.59B 6.99B 6.84B 6.38B 6.00B
Total Liabilities 1.51B 1.33B 1.89B 1.77B 1.74B
Shareholders' Equity 6.09B 5.66B 4.95B 4.60B 4.27B
Total Debt 642.87M 649.47M 1.10B 1.09B 1.09B
Cash & Equivalents 1.31B 942.84M 755.13M 724.53M 587.28M
Current Assets 3.95B 3.23B 2.96B 2.75B 2.27B
Current Liabilities 759.03M 606.99M 1.18B 588.88M 546.50M

Puntuaciones de Estrategias

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#699 of 1052
37

Actividad Reciente

Entró Cash Flow Compounder
Mar 24, 2026